Biotech company Ginkgo Bioworks Holdings, Inc. (DNA) develops the leading horizontal platform for cell programming. The company’s platform is used to program cells to enable the biological production of products, including novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves several end markets, such as specialty chemicals, food, agriculture, consumer products, and pharmaceuticals.
DNA has declined 71.1% in price year-to-date and 74.9% over the past year to close the last trading session at $2.51. The stock is currently trading 84.2% below its 52-week high of $15.86, which it hit on November 9, 2022.
